Novartis AG

Novartis AG(NVS)資訊與事件

$150.380

+3.579 (+2.38%)收盤時

NVS 資訊

NVS 事件

10/7 12:00

Novartis' Rhapsido Approved by FDA for Adult Dermographism

Novartis announced that the Food and Drug Administration approved Rhapsido as the first treatment for adults with symptomatic dermographism inadequately controlled by H1 antihistamines. Rhapsido is now the only treatment indicated for the two most common forms of chronic hives: chronic spontaneous urticaria and symptomatic dermographism, the company said in a statement.

10/7 07:30

Novartis to Present 46 MS Research Data at MSToronto2026

Novartis will present new data from its multiple sclerosis, MS, portfolio with 46 abstracts at MSToronto2026, the 10th Joint ACTRIMS-ECTRIMS Meeting. Among these is a late-breaking abstract featuring the Phase III REMODEL-1/-2 results, underscoring the potential of remibrutinib and reinforcing the company's long-standing commitment to advancing care for people living with MS. A second late-breaking abstract will present new Kesimpta data in pediatric MS. Additional presentations will further expand the Kesimpta evidence base, including research on pregnancy outcomes and breastfeeding that aims to inform family planning decisions, as well as the use of Kesimpta versus disease-modifying therapies commonly used as first-line treatments in treatment-naive patients.

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易